Literature DB >> 12199783

Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.

Athanasios B-T Fassas1, Tray Spencer, Jeffrey Sawyer, Maurizio Zangari, Choon-Kee Lee, Elias Anaissie, Firas Muwalla, Christopher Morris, Bart Barlogie, Guido Tricot.   

Abstract

Complete or partial deletion of chromosome 13 or translocations involving 13q (delta13) by conventional cytogenetic analysis confers a poor prognosis in multiple myeloma (MM) patients, even with timely application of tandem autologous transplants. It was recently suggested that the prognostic significance of delta13 is related to its frequent association with hypodiploidy but by itself does not have a poor prognostic significance. We therefore analysed our experience in 1475 consecutive MM patients in whom we intended treatment with tandem transplants after a melphalan-based conditioning regimen. Patients with abnormal cytogenetic analysis were grouped into hypodiploid/hypotetraploid, pseudodiploid and hyperdiploid groups, according to their modal chromosome number. Their event-free and overall survival were compared with those of patients with a normalkaryotype. Both hypodiploidy and delta13 were found to independently confer poor prognosis in MM patients. Furthermore, these parameters in combination with easily obtained pretransplant levels of beta-2 microglobulin and albumin define three groups of MM patients with clearly distinct outcomes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12199783     DOI: 10.1046/j.1365-2141.2002.03757.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  25 in total

1.  Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

Authors:  Miki Kiyota; Tsutomu Kobayashi; Shinichi Fuchida; Mio Yamamoto-Sugitani; Muneo Ohshiro; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Nana Sasaki; Ryuko Nakayama; Yoshiaki Chinen; Natsumi Sakamoto; Hitoji Uchiyama; Yosuke Matsumoto; Shigeo Horiike; Chihiro Shimazaki; Junya Kuroda; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2012-03-17       Impact factor: 2.490

2.  A case of aggressive myeloma recognized shortly after the remission following high-dose chemotherapy with autologous peripheral blood stem cell transplantation.

Authors:  Kaname Ueda; Katsuhiro Miura; Yoshihiro Hatta; Sumiko Kobayashi; Toshitake Tanaka; Atsuko Hojo; Hikaru Ishizuka; Umihiko Sawada; Yoshimasa Kura; Jin Takeuchi
Journal:  Int J Hematol       Date:  2010-08-20       Impact factor: 2.490

Review 3.  Autologous stem cell transplantation in hematological malignancies.

Authors:  Norbert-Claude Gorin
Journal:  Springer Semin Immunopathol       Date:  2004-10-07

4.  Short or long survival in multiple myeloma. A simple method for determining the prognosis.

Authors:  Judit Várkonyi; Edina Bajzik; Adám Fazakas; Sándor Sipka; István Karádi
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

Review 5.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

6.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

7.  Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study.

Authors:  Ji Myung Kim; Jung Ae Lee; In Sung Cho; Chun Hwa Ihm
Journal:  Korean J Hematol       Date:  2010-06-30

8.  Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.

Authors:  Scott Van Wier; Esteban Braggio; Angela Baker; Gregory Ahmann; Joan Levy; John D Carpten; Rafael Fonseca
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

9.  Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

Authors:  George E Georges; Michael B Maris; David G Maloney; Brenda M Sandmaier; Mohamed L Sorror; Judith A Shizuru; Thoralf Lange; Edward D Agura; Benedetto Bruno; Peter A McSweeney; Michael A Pulsipher; Thomas R Chauncey; Marco Mielcarek; Barry E Storer; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2007-02-01       Impact factor: 5.742

Review 10.  Front-line treatment in younger patients with multiple myeloma.

Authors:  S Vincent Rajkumar; Pieter Sonneveld
Journal:  Semin Hematol       Date:  2009-04       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.